RxDoctor Payments Data

Victoria Arlauskas, MD

Internal Medicine · Spartanburg, SCNPI 1861444218

Payments from drug & device makers

$8,765in general payments, 2019–2025

Across 578 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$871
  • AstraZeneca$774
  • Novo Nordisk$615
  • Amgen$566
  • GSK$484
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,70699%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,765 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$376,558
Medicare patients
910
Services billed
10,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban493$427,000
OzempicSemaglutide358$404,579
SkyclarysOmaveloxolone11$353,047
MounjaroTirzepatide192$214,160
FarxigaDapagliflozin Propanediol217$173,763
JardianceEmpagliflozin147$127,442
XareltoRivaroxaban132$115,041
Diclofenac Sodium222$76,841
JanuviaSitagliptin Phosphate75$71,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$69,778
LinzessLinaclotide85$61,833
MyrbetriqMirabegron82$55,662
TrintellixVortioxetine Hydrobromide60$43,872
TrulicityDulaglutide32$32,429
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog42$31,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$871$449,091509 claims
Novo NordiskOzempic, Rybelsus$615$432,484381 claims
Lilly USA, LLCMounjaro, Trulicity$322$246,589224 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$774$212,442286 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$168$168,895201 claims
Johnson & JohnsonXarelto$23$115,041132 claims
GSKTrelegy Ellipta, Breo Ellipta$484$88,946119 claims
AbbVieLinzess, Synthroid$1,300$85,156426 claims
MerckJanuvia$71$71,65775 claims
Astellas Pharma US IncMyrbetriq$167$55,66282 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$390$43,87260 claims
Sumitomo Pharma America, Inc.Gemtesa$247$31,28149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →